L’équipe EpiDermE représentée par Émilie Sbidian, Léa Hoisnard, Thomas Bettuzzi, Quentin Beytout et Robin Guelimi sera présente au congrès de la SFPT (Société Française de Pharmacologie et de Thérapeutique ), qui aura lieu à Tours du mardi 11 au jeudi 13 juin 2024.
La team présentera des communications orales et/ou des posters. Félicitations à Léa pour son prix de thèse et à Quentin pour son prix de M2 !
Mardi 11 juin
Léa Hoisnard – Communication orale – Pharmaco-épidémiologie – 13h30
Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study
Thomas Bettuzzi – Poster – Pharmaco-épidémiologie – 15h00
Incidence, in-hospital and long-term mortality and sequelae of epidermal necrolysis in adult patients in France: a French insurance database cohort study
Quentin Beytout – Poster – Pharmaco-épidémiologie – 15h00
Quality of reporting and concordance between sources of adverse events in the
treatment of moderate-to-severe psoriasis: a systematic review
Robin Guelimi – Poster – Méthodologie, pharmacologie clinique – 15h00
Association between funding and conclusions of network meta-analyses evaluating targeted therapies in chronic immune-mediated inflammatory diseases : an overview
Émilie Sbidian – Modération – Table ronde HAS / ANSM – 16h00
Développement & régulation – Place des données observationnelles dans la prise de décision
Mercredi 12 juin
Léa Hoisnard – Prix de thèse – 09h30
Safety of targeted therapies for treating immune mediated inflammatory diseases
Thomas Bettuzzi – Poster – Pharmaco-épidémiologie – 10h00
Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: a pharmacovigilance study
Thomas Bettuzzi – Poster – Pharmaco-épidémiologie – 10h00
Relapses and rechallenge of suspected drugs in epidermal necrolysis patients: a population based-study in France
Quentin Beytout – Prix de M2 – 16h00
Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a systematic review